Profil
Brian R Bond has held positions as President & CEO at Gateway Pharmacology Laboratories LLC and Senior Director-Cardiorenal Pharmacology at Inotiv, Inc.
Postes actifs de Brian R Bond
| Sociétés | Poste | Début |
|---|---|---|
| INOTIV, INC. | Corporate Officer/Principal | - |
Gateway Pharmacology Laboratories LLC
 Gateway Pharmacology Laboratories LLC Miscellaneous Commercial ServicesCommercial Services Part of Inotiv, Inc., Gateway Pharmacology Laboratories LLC conducts studies to establish proof of concept, define exposure/response relationships, and characterize safety using validated rodent models of pharmacology and disease. Gateway Pharmacology Laboratories is based in Chesterfield, MO. The private company can fully customize and develop new methods and research models to fulfill unique project needs. The company is committed to providing quality and timely results and building productive relationships with their clients. The company specializes in discovery pharmacology for cardiovascular, renal, hepatic, metabolic, and inflammatory diseases, as well as safety pharmacology for blood pressure, heart function, ECG, renal safety, and chronic infusion PK/PD/biomarkers. The CEO of the company is Brian R Bond. The company was acquired by Inotiv, Inc. on August 02, 2021. | Chief Executive Officer | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INOTIV, INC. | Commercial Services |
| Entreprise privées | 1 |
|---|---|
Gateway Pharmacology Laboratories LLC
Gateway Pharmacology Laboratories LLC Miscellaneous Commercial ServicesCommercial Services Part of Inotiv, Inc., Gateway Pharmacology Laboratories LLC conducts studies to establish proof of concept, define exposure/response relationships, and characterize safety using validated rodent models of pharmacology and disease. Gateway Pharmacology Laboratories is based in Chesterfield, MO. The private company can fully customize and develop new methods and research models to fulfill unique project needs. The company is committed to providing quality and timely results and building productive relationships with their clients. The company specializes in discovery pharmacology for cardiovascular, renal, hepatic, metabolic, and inflammatory diseases, as well as safety pharmacology for blood pressure, heart function, ECG, renal safety, and chronic infusion PK/PD/biomarkers. The CEO of the company is Brian R Bond. The company was acquired by Inotiv, Inc. on August 02, 2021. | Commercial Services |
